Get started
11/6/24 - $yeti - i'm a buyer into print. good value at ~10% fcf11/6/24 :: VROCKSTAR :: NYSE:YETI i'm a buyer into print. good value at ~10% fcf yield - keeping it simple - tariffs matter for a number of consumer names on trump win - "okay". but you see NASDAQ:MCFT 's results? boats and beers are strong, consumer spending, yeti demo has more $ than the five below bros (no disrespect, i love the candy selection there) - but anyway 10% fcf yield and good stock comp control PLUS big short interest in this has me taking a LT position here - let's see what results bring and we react accordingly - but i like the R/R here while the mkt is probably working thru some more flows-related hedges, baskets for hedgies etc. etc. - what do u think? - oh. long NYSE:ELF too... but that's a diff story and i'm not gonna write it up. and while i'm at it, took a small bite of NASDAQ:CROX even tho i'd still like to see it lower. V
NYSE:YETILong
by VROCKSTAR
DAL... We have take offGood morning traders, If you have been following my predictions on DAL and UAL, well... WE HAVE TAKE OFF! OB has been tested, we could see a pullback testing the previous red candle but should be a decent flight from there on out. Some turbulence along the way, but shouldn't be big enough to knock this plane down. All previous areas have been tested and structurally it looks great. Hang on tight a bit more we are almost there. Keep UAL on your sights, this has much more traveling to do which means bigger profits as well. Hope you enjoy the rest of your day, and don't forget to follow for all my other predictions. Have a great rest of your week, happy trading & God Bless!
NYSE:DALLong
by Vic_Tech_Trader
AMLX - Pre Catalyst Run up Play with massive GAP!Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder. Shares float: 61.87M Topline Data 16/10/2024 ET Phase 2 topline data to be presented at ISPAD October 16-19, 2024. Phase 2 first patient dosed April 13, 2023. Phase 2 enrollment completed, noted February 8, 2024. Phase 2 data demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression, noted April 10, 2024. 2 more catalysts end of August 2025 and end of December 2025 Huge down gap from $18.00 to $4.50 Breakout and Entry Zone above: $2.60 Action: If the stock breaks above this area with strong volume, it might signal a continuation of the upward trend. Overall Market Sentiment: Currently, the market seems to be in a correction phase. It’s crucial to consider this sentiment when making trading decisions. Resistance Points: $3.00 $3.90 $4.50 $6.50 $8.50 $10.00 $11.50 $13.00 $15.50 Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains. Trading Strategy: Take Profit (TP): Set a target at $6.50 (pre catalyst run up) and if we see a full gap fill set a second one at $18.00 (highly speculative and could take time) Stop Loss (SL): Set at under $1.70 to mitigate potential losses. Chart Analysis: Please refer to the attached chart for detailed analysis of price trends and movements. Trading Advisory: Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities. Disclaimer: This content is for informational purposes only and should not be considered financial advice.
NASDAQ:AMLXLong
by meitshels_smell_trades
WFC pullback to $64MODs have suggested that I provide more detail about the picks I make. Sorry. I'm not as verbose as y'all, and I don't like things to be complicated. My trading plan is very simple. I buy or sell at top & bottom of parallel channels. I confirm when price hits Fibonacci levels. Bonus if a TTM Squeeze in in play. I hold until target is reached or end of year, when I can book a loss. So... Here's why I'm picking this symbol to do the thing. Price above channels (period 100 52 39 & 26) Stochastic Momentum Index (SMI) at overbought level VBSM spiked positive Price at/near Fibonacci level In at $73.33 Target is $64.43 or channel bottom Stop loss is $76
NYSE:WFCShort
by chancethepug
SLB 5M Daytrade Long Aggressive CounterTrend tradeAggressive CounterTrend trade - short impulse + support level - unvolumed T1 level + volumed 2Sp- - weak test closed below T1 + first bullish bar closed entry - target beyond 5M / 1H range Calculated affordable stop limit 1 to 2 R/R take profit expandable to swing / investment trade 1 Hour CounterTrend "- short balance + expanding ICE + support level + biggest volume manipulation" 1 Day Trend "+ long impulse + SOS test level + support level + 1/2 correction" 1 Month Trend "+ long balance + expanding ICE level + support level + 1/2 correction + volumed manipulation" Sell SLB Limit 44.54, GTC Sell SLB Stop 42.29 LMT 43.06, GTC
NYSE:SLBLong
by MishaSuvorov
Zscaler: Wave (2) Correction! After a rapid rise in early September, the ZS stock managed to reach the highs from August, but there was no significant acceptance at this level. Structurally, the upward movement isn't sufficient for us to consider wave (2) as completed. So far, the bullish signals lack a clear impulsive character, and we expect new lows during the magenta wave (2), which should primarily end above the support at $84.93. Once a trend reversal has been initiated, the subsequent wave (3) should push through the resistance at $251.45. According to our 33% likely alternative scenario, this could also happen directly.
NASDAQ:ZS
by MarketIntel
IBKR: BUY THE TECHY BROKERNASDAQ:IBKR reported strong results for Q3 2024, with adjusted earnings per share of $1.75, reflecting a 12.9% increase from the prior year, albeit slightly below the consensus estimate of $1.78. The company has shown significant growth in customer accounts and daily average revenue trades (DARTs), key drivers behind its performance. After an initially negative reaction to the earnings report due to the slight miss and overall market trends, shares are stabilizing today. This creates a brief window for a long trade, allowing for a tight stop level to establish a very favorable risk-reward scenario. Key Highlights Supporting Further Gains: Total Revenue: $1.37 billion, up 19.2% year-over-year. Customer Accounts: Grew 28.3% to 3,120,000 accounts. DARTs: Increased 41.7% to 2.7 million, aligning with expectations. Strong Capital Position: Cash and equivalents total $69.9 billion, with total assets of $148.5 billion. Daily Technical Analysis Overview: Oscillators: RSI (14): 66.07 (Neutral) Momentum (10): 4.72 (Buy) Bull Bear Power: 2.08 (Buy) Moving Averages: EMA (10, 20, 50, 100, 200): All in "Buy." SMA (10, 20, 50, 100, 200): All in "Buy." Conclusion: The robust capital position of Interactive Brokers, along with growth in accounts and DARTs, supports a positive outlook for the stock. Despite a slight increase in expenses, the fundamentals remain strong, justifying a buy recommendation. This is a great opportunity to capitalize on the current trend pause. If you'd like to discuss stop levels or have any questions, feel free to reach out! 🚀 Don’t miss this opportunity and follow me for more trading ideas! Disclaimer: This analysis and recommendation are for informational purposes only and do not constitute financial advice. Always conduct your own research and consult with a financial advisor before making any investment decisions. Past performance is not indicative of future results. Investing in stocks involves risks, including the loss of principal.
NASDAQ:IBKRLong
by CF_444
Incoming 60% correction for ASML HoldingOn the above weekly chart price action has seen a strong 200% upward move since 2022. No doubt a move in part caused by the AI mania. Is now a good time to buy? Seeking alpha says “Buy the dip” “ASML has returned to growth after revenue declines, with flat revenue expected for 2024 and growth anticipated in 2025, driven by new EUV tools.” “Despite a 53% QoQ drop in net bookings, ASML's backlog remains strong at €36B, supporting a revised 2025 revenue outlook of €30-35B.” A quick Google leads to no shortage of “buy the dip” articles. But then again, Google is not what it once was, with many paid for bias articles are evident. The best News and outlook will always be the chart. On the above weekly chart: 1) Price action and RSI support failures. 2) Broken market structure. 3) Look left, support and resistance, red arrows. The 2021 market top confirms resistance in October 2024. This is a significant warning. 4) The bear flag. It is has not yet confirmed, but a breakout is evident. A back test would be ideal, towards $800 area. The flag forecasts a 60% correction to support. Is it possible price action continues to rise? Sure. Is it probable? No. Ww Type: trade, short from $800
NASDAQ:ASMLShort
by without_worries
5
Catch the Wave - "1986 Coca-Cola Slogan"Hello TradingView Family / Fellow Traders. This is Richard, also known as theSignalyst. 📈KO has been overall bullish, trading above the red trendline. Moreover, it is approaching a demand zone marked in red. 🏹 The highlighted red circle is a strong area to look for buy setups as it is the intersection of the demand zone and red trendline acting as a non-horizontal support. 📚 As per my trading style: As #KO approaches the red circle zone, I will be looking for bullish reversal setups (like a double bottom pattern, trendline break , and so on...) 📚 Always follow your trading plan regarding entry, risk management, and trade management. Good luck! All Strategies Are Good; If Managed Properly! ~Rich
NYSE:KOLong
by TheSignalyst
1